Article
Radiology, Nuclear Medicine & Medical Imaging
Michael D. Farwell, Raymond F. Gamache, Hasan Babazada, Matthew D. Hellmann, James J. Harding, Ron Korn, Alessandro Mascioni, William Le, Ian Wilson, Michael S. Gordon, Anna M. Wu, Gary A. Ulaner, Jedd D. Wolchok, Michael A. Postow, Neeta Pandit-Taskar
Summary: This study demonstrates that CD8 PET imaging with Zr-89-Df-IAB22M2C is a safe and effective method for visualizing the whole-body biodistribution of CD8+ leukocytes in tumors and reference tissues, and may predict early response to immunotherapy.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Bastien Nguyen, Christopher Fong, Anisha Luthra, Shaleigh A. Smith, Renzo G. DiNatale, Subhiksha Nandakumar, Henry Walch, Walid K. Chatila, Ramyasree Madupuri, Ritika Kundra, Craig M. Bielski, Brooke Mastrogiacomo, Mark T. A. Donoghue, Adrienne Boire, Sarat Chandarlapaty, Karuna Ganesh, James J. Harding, Christine A. Iacobuzio-Donahue, Pedram Razavi, Ed Reznik, Charles M. Rudin, Dmitriy Zamarin, Wassim Abida, Ghassan K. Abou-Alfa, Carol Aghajanian, Andrea Cercek, Ping Chi, Darren Feldman, Alan L. Ho, Gopakumar Iyer, Yelena Y. Janjigian, Michael Morris, Robert J. Motzer, Eileen M. O'Reilly, Michael A. Postow, Nitya P. Raj, Gregory J. Riely, Mark E. Robson, Jonathan E. Rosenberg, Anton Safonov, Alexander N. Shoushtari, William Tap, Min Yuen Teo, Anna M. Varghese, Martin Voss, Rona Yaeger, Marjorie G. Zauderer, Nadeem Abu-Rustum, Julio Garcia-Aguilar, Bernard Bochner, Abraham Hakimi, William R. Jarnagin, David R. Jones, Daniela Molena, Luc Morris, Eric Rios-Doria, Paul Russo, Samuel Singer, Vivian E. Strong, Debyani Chakravarty, Lora H. Ellenson, Anuradha Gopalan, Jorge S. Reis-Filho, Britta Weigelt, Marc Ladanyi, Mithat Gonen, Sohrab P. Shah, Joan Massague, Jianjiong Gao, Ahmet Zehir, Michael F. Berger, David B. Solit, Samuel F. Bakhoum, Francisco Sanchez-Vega, Nikolaus Schultz
Summary: This study investigates the genomic mechanisms driving metastasis in cancer patients. By analyzing a cohort of over 25,000 patients with metastatic diseases, the researchers identify associations between genomic alterations and patterns of metastatic dissemination across different tumor types. The study highlights the complex role of chromosomal instability in cancer progression and provides valuable insights for further research on metastatic spread.
Article
Oncology
Funda Meric-Bernstam, Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan, Angela DeMichele, Naomi B. Haas, Manish R. Patel, James J. Harding, Martin H. Voss, Taofeek K. Owonikoko, Bradley Carthon, Ramaprasad Srinivasan, Johanna C. Bendell, Yonchu Jenkins, Sam H. Whiting, Keith Orford, Mark K. Bennett, Todd M. Bauer
Summary: TelaE and TelaC showed promising clinical activity and tolerability in heavily pretreated metastatic renal cell carcinoma patients.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Valentina Boni, Mary J. Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E. Sanborn, Randy F. Sweis, Patricia LoRusso, Misako Nagasaka, Javier Garcia-Corbacho, Shadia Jalal, James J. Harding, Stella K. Kim, Iris H. C. Miedema, Danielle J. Vugts, Marc C. Huisman, Gerben J. C. Zwezerijnen, Guus A. M. S. van Dongen, C. Willemien Menke van der Houven van Oordt, Song Wang, Tam Dang, Ivan A. Zein, Olga Vasiljeva, Susan K. Lyman, Virginia Paton, Alison Hannah, Joyce F. Liu
Summary: The purpose of this study was to evaluate the efficacy and safety of Praluzatamab ravtansine (CX-2009) in patients with advanced solid tumors. The results showed that breast cancer was the most prevalent subtype among the 99 patients enrolled in the study.
CLINICAL CANCER RESEARCH
(2022)
Meeting Abstract
Oncology
James J. Harding, Hooman Yarmohammadi, Kim Anna Reiss, Joanne F. Chou, Marinela Capanu, Richard K. G. Do, Danny Khalil, Imane H. El Dika, Christine S. Ferrer, Olivia Heffernan, J. Daniel Giardina, Taha Merghoub, William R. Jarnagin, Gregory Nadolski, Joseph Patrick Erinjeri, Michael C. Soulen, Benjamin R. Tan, Ghassan K. Abou-Alfa
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
James J. Harding, Ralf-Dieter Hofheinz, Elena Elez, Yasutoshi Kuboki, Drew W. Rasco, Michael Cecchini, Lin Shen, Elizabeth Dowling, Shorena Archuadze, Bruna Andrade de Pereira, Shubham Pant
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Thomas Yau, Joong-Won Park, Richard S. Finn, Ann-Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, James J. Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, Eckart Schott, Su Pin Choo, Robin Kate Kelley, Wolfgang Sieghart, Eric Assenat, Renata Zaucha, Junji Furuse, Ghassan K. Abou-Alfa, Anthony B. El-Khoueiry, Ignacio Melero, Damir Begic, Gong Chen, Jaclyn Neely, Tami Wisniewski, Marina Tschaika, Bruno Sangro
Summary: First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma, but clinical activity and a favorable safety profile were observed in some patients.
Article
Gastroenterology & Hepatology
James J. Harding, Danny N. Khalil, Luca Fabris, Ghassan K. Abou-Alfa
Summary: Biliary tract cancers are rare gastrointestinal malignancies associated with high morbidity and mortality rates. Various treatments, including chemotherapy, precision medicine, and immunotherapy, are used in both standard-of-care and investigational settings. Recent research has shown that the combination of durvalumab with gemcitabine and cisplatin improves survival outcomes. Precision medicine is utilized in patients with specific genetic alterations, while fluoropyridine doublets are used in patients without targetable genetic alterations. Next-generation sequencing is crucial for patient care and understanding resistance mechanisms. Ongoing clinical trials seek to improve treatment standards and develop effective combination drug therapies for the future.
JOURNAL OF HEPATOLOGY
(2023)
Article
Oncology
James J. J. Harding, Christiane Jungels, Jean-Pascal Machiels, David C. C. Smith, Chris Walker, Tao Ji, Ping Jiang, Xin Li, Ekaterine Asatiani, Eric Van Cutsem, Ghassan K. K. Abou-Alfa
Summary: This study investigated the safety, tolerability, and maximum tolerated dose of INCB062079, an oral selective FGFR4 inhibitor, in patients with advanced solid tumors. The results showed that the drug demonstrated a manageable safety profile and inhibited tumor growth at appropriate doses. However, the study was terminated prematurely due to difficulties in patient recruitment.
Article
Multidisciplinary Sciences
James J. Harding, Sarina A. Piha-Paul, Ronak H. H. Shah, Jessica J. Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Brana, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Monica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael F. Berger, Lisa D. Eli, Funda Meric-Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou-Alfa
Summary: In patients with biliary tract cancer, HER2 alterations correlate with poor prognosis. A phase II clinical trial showed that the tyrosine kinase inhibitor neratinib has some efficacy in treating advanced biliary tract cancers with HER2-mutation positive. The objective response rate to neratinib was 16% (95% CI 4.5-36.1%).
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Kevin C. Soares, Joshua S. Jolissaint, Sarah M. McIntyre, Kenneth P. Seier, Mithat Gonen, Carlie Sigel, Naaz Nasar, Andrea Cercek, James J. Harding, Nancy E. Kemeny, Louise C. Connell, Bas Groot Koerkamp, Vinod P. Balachandran, Michael I. D'Angelica, Jeffrey A. Drebin, T. Peter Kingham, Alice C. Wei, William R. Jarnagin
Summary: The role of locoregional therapy versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma remains controversial. This study compared overall survival in patients treated with resection, hepatic arterial infusion pump chemotherapy, or systemic chemotherapy, and evaluated the efficacy of locoregional salvage therapy. The findings highlight the importance of hepatic disease control and the potential benefits of liver-directed therapy.
Article
Ophthalmology
Jasmine H. Francis, William Foulsham, Julia Canestraro, James J. Harding, Eli L. Diamond, Alexander Drilon, David H. Abramson
Summary: This study compared the clinical and morphologic characteristics of serous retinal disturbances in patients taking different types of MAPK inhibitors. It found that all patients exhibited bilateral, fovea-involving, and reversible subretinal fluid foci, regardless of the type of inhibitor used. The downstream targets (MEK or ERK inhibitors) showed higher incidence, more fluid foci, more intraretinal edema, and more symptomatic patients compared to the upstream target (FGFR inhibitors).
OCULAR ONCOLOGY AND PATHOLOGY
(2023)
Article
Oncology
Bruno Almeida Costa, Paulino Tallon de Lara, Wungki Park, Fergus Keane, James J. Harding, Danny N. Khalil
Summary: Despite advances in surveillance and management, advanced cholangiocarcinoma still has a poor prognosis. Recent studies have identified actionable genomic alterations, such as homologous recombination deficiency (HRD), that can affect treatment response. This case report discusses a patient with BRCA2-mutant CCA who showed a durable response to olaparib, a PARP inhibitor, after intolerable toxicity with gemcitabine/cisplatin. Further clinical trials are needed to confirm the role of PARP inhibition in similar patients.
ONCOLOGY RESEARCH AND TREATMENT
(2023)
Article
Medical Laboratory Technology
Enaksha Wickremsinhe, Antoniu Fantana, Erwin Berthier, Brook A. Quist, Diego Lopez de Castilla, Charles Fix, Kahlil Chan, Jing Shi, Michael G. Walker, Jennifer F. Kherani, Holly Knoderer, Arie Regev, James J. Harding
Summary: This study evaluated the use of the capillary blood collection device Tasso+ for measuring abnormal liver function. The results showed that Tasso+ demonstrated high concordance with standard venipuncture and provided a positive patient experience.
JOURNAL OF APPLIED LABORATORY MEDICINE
(2023)
Article
Immunology
James J. Harding, Ignacio Garrido-Laguna, Xiaoying Chen, Cynthia Basu, Afshin Dowlati, Alison Forgie, Andrea T. Hooper, Cris Kamperschroer, Steven I. Max, Allison Moreau, Megan Shannon, Gilbert Y. Wong, David S. Hong
Summary: P-cadherin is overexpressed in solid tumors, and PF-06671008 shows antitumor activity by engaging P-cadherin and CD3 epsilon. This phase 1 study evaluates the safety and tolerability of PF-06671008 and provides insights into managing immune-related adverse events. Limited antitumor activity and cytokine release syndrome were observed.
FRONTIERS IN IMMUNOLOGY
(2022)
